Novel therapeutics in the treatment of hairy cell leukemia variant

Hairy cell leukemia variant (vHCL) is a B-cell lymphoproliferative disorder. The 2016 US lymphoid malignancy statistics estimate that vHCL was diagnosed in 810 patients, with an age adjusted US standard population incidence of approximately 0.2 per 100,000 [1]. Prior to 2008, when the World Health Organization classified vHCL as a provisional diagnosis, hairy cell leukemia encompassed both classic hairy cell leukemia (cHCL) and vHCL. These two entities exhibit unique morphological, cytological and hematologic findings and are not considered to be biologically related.
Source: Leukemia Research - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research